Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Pharmaceutical
The National Institute for Health and Care Excellence's (NICE) consultation on the proposed changes to its methods and processes of health technology assessment closed on October 13. Here Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, provides an Expert View on the proposed fresh approach to health technology assessment and how this will allow continued fair and fast access to medicines in the National Health Service (NHS). 5 November 2021
Pharmaceutical
Paul Domenet, partner and communications creative director at Free The Birds, offers an Expert View on how big pharma can improve its image. 26 October 2021
Pharmaceutical
The news cycle has hit overdrive in the UK ahead of a frenetic couple of weeks that include the Autumn Budget, a Comprehensive Spending Review and the COP26 conference in Glasgow. 26 October 2021
Pharmaceutical
An Expert View from Gary Connors, partner at Oliver Wight, on intellectual property rights protection and drug development. 15 October 2021
Pharmaceutical
Carima Andrady, senior regulatory writer at PharmaLex, provides an Expert View on a key consideration when seeking to secure an Orphan Drug designation (ODD) in Europe. 8 October 2021
Pharmaceutical
Uwe Trinks, global practice lead for pharmacovigilance technologies, IQVIA, provides an Expert View on how the pharmaceutical industry can make a success of new working practices. 21 September 2021
Biotechnology
Kees Melief, chief scientific officer of ISA Pharmaceuticals, provides an Expert View on why therapeutic cancer vaccines will be a success following many years of being out of favor. 3 September 2021
Pharmaceutical
Eva Marchese, Abhishek Kumar and Kees Chamberlain from Charles River Associates examine how the COVID-19 pandemic is expected to impact payers’ management of pharmaceutical budgets in Europe in an Expert View column. 26 August 2021
Pharmaceutical
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
Pharmaceutical
Luke Robinson, relationship manager at Included, tackles an important issue for the sector in an Expert View piece. 3 August 2021
Pharmaceutical
An Expert View on the pros and cons of intellectual property (IP) protections in the pharmaceutical sector from White & Case partners' competition lawyer, James Killick, chair of the firm’s IP practice, Anita Varma, and associate and member of the Global Competition practice group, Alexander Krois. 20 July 2021
Pharmaceutical
Merlin Piscitelli, chief revenue officer for EMEA at Datasite, provides an Expert View on M&A trends and predictions for deal-making in life sciences, and some of the challenges we may expect. 1 July 2021
Pharmaceutical
Over the past few decades, there’s hardly a sector that has not been revolutionized by technology in some way, shape or form. When we think about tech innovation, we imagine seismic steps that disrupt market conditions and fundamentally reshape entire industries. 22 June 2021
Biotechnology
In an environment with continued pricing pressure biopharma executives are asking themselves: Can we discover and develop new medicines that improve patient outcomes whilst solving access challenges? 17 June 2021
Pharmaceutical
An Expert View from Mark Doyle, co-founder of UK company The Method and creator of A Life in a Day experience, which seeks to support the pharmaceutical and healthcare industries in developing patient-centric strategies for more impactful engagement. 7 June 2021
Pharmaceutical
AJ Ploszay, vice president of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by the digital buying trends driven by COVID-19, are influencing a similar shift in the commercial pharma space. 20 May 2021
Pharmaceutical
An Expert View from Manjit Singh, chairman of the Pharmaceutical Supply Chain Initiative, which tries to foster responsible supply chains, highlighting the issue of antibiotic resistance and the often-underestimated threat coming from the discharge of material in environment. 14 May 2021
Pharmaceutical
Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boards isn’t just a numbers game. Women bring diverse perspectives that are needed more than ever. 7 May 2021
Pharmaceutical
Nicola Mahy, director at Align Strategy, makes the case for an integrated evidence plan to maximize patient access to a brand in an Expert View piece. 21 April 2021
Pharmaceutical
Hannah Schofield, associate at Hogan Lovells, considers the option of utilizing blockchain technology for accurate tracking and monitoring in an Expert View piece. 7 April 2021
Pharmaceutical
As leaders gather in Davos, it can feel like a lifetime since three feet of distance defined daily life. Yet it was only six years ago, and the lessons of the COVID-19 pandemic remain uncomfortably relevant. Preparedness for future pandemics must embed a full range of medical countermeasures into readiness planning. 14 January 2026
Pharmaceutical
An Expert View from Steve Bulera, CVP and CSO, Discovery and Safety Assessment, Charles River. 8 January 2026
Biotechnology
Neok Biotech’s $75 million series A venture round, which took the California-based biotech out of stealth mode, was not the largest fundraising event in November. However, it highlighted a rapidly growing investment trend: the rise of the NewCo. 24 December 2025
Pharmaceutical
According to market research, the mitochondrial therapeutics market is valued at $2.32 billion in 2025. It is projected to reach $5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1). 22 December 2025
Pharmaceutical
An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life Sciences and partner. 18 December 2025
Generics
For decades, the generics industry has been dedicated to supporting the financial sustainability of health systems. By delivering high-quality, affordable alternatives at scale, generics have helped protect treatment access and enabled health services to meet growing demand without compromising standards of care. 11 December 2025
Pharmaceutical
An Expert View from Michelle Murray, Vice President Health, Value & Access, GSK UK Commercial. 9 December 2025
Pharmaceutical
An Expert View from Alistair Henry, executive vice president, chief scientific officer and head of patient solutions, UCB. 7 December 2025
Pharmaceutical
In today’s rapidly evolving healthcare landscape, the journey from scientific discovery to patient access is more complex than ever. For medicines to reach those who need them most, especially in areas of high unmet need, pharmaceutical companies must embrace innovation not only in their science but in their approach to access, collaboration, and delivery. 11 November 2025
Pharmaceutical
Pharmacovigilance (PV) is a crucial process used by pharmaceutical companies, healthcare professionals and regulators in identifying, evaluating and preventing adverse drug reactions. 3 November 2025
Pharmaceutical
In 2014, I sat in a room at a “Genetic Networks” conference listening to Brendan Frey present his talk titled Decoding the Genetic Determinants of Human Disease. Brendan presented data from his 2015 paper that AI had “decoded biology”, solved part of the splicing problem and could help to replace many experiments - we just needed to go out and apply it. I remember the optimism, but thought that there’s no way that these efforts had involved the realities of wet-lab work, let alone the more difficult constraints of drug discovery. 20 October 2025
Pharmaceutical
An Expert View from Agnese Cattaneo, Chief Medical Officer at Angelini Pharma. 10 October 2025
Pharmaceutical
An Expert View from Mary Kosinski, Global Managing Director, Health & Life Sciences, FleishmanHillard. 25 September 2025
Pharmaceutical
An Expert View from Ramji Vasudevan, head of life sciences, Altimetrik. 19 September 2025
Pharmaceutical
An Expert View from Lindsay Mateo, chief commercial officer at Weave Bio. 12 August 2025
Pharmaceutical
In the high-stakes world of drug development, a pill is never just a pill. Every oral drug that reaches the market has passed through a tightly managed series of steps—none more critical, or more vulnerable, than tech transfer. 15 July 2025
Biotechnology
An Expert View from Justin Kozak, life sciences industry lead, Founder Shield. 4 July 2025
Pharmaceutical
In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View. 26 June 2025
Pharmaceutical
A typical advertisement for a prescription drug airs on television. The visuals are lively and upbeat; the people are smiling and confident. But the viewer walks away with no clear understanding of what the drug treats. Within moments, the ad is forgotten. 30 May 2025
Pharmaceutical
This week, Dr Kimberly Smith, Senior Vice President, Chief Scientific Officer, Head of Research & Development at ViiV Healthcare, provides an Expert View on how, through a deep understanding of the HIV community, the company has led the way in changing the HIV treatment and prevention paradigm. 23 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze